Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Gdansk
Clinical trial register · Poland

Clinical Trials in Gdansk, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2705 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC
2705
Studies in scope
all four open statuses
1389
Recruiting now
open to new participants
512
Lead sponsors
across recruiting studies
Top sites
Warsaw 95 Lodz 80 Krakow 70 Poznan 67 Gdansk 59
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca59 Medical University of Gdansk32 Janssen Research & Development, LLC30 Merck Sharp & Dohme LLC27 Hoffmann-La Roche24 Clear sponsor filter
Site location
Warsaw95 Lodz80 Krakow70 Poznan67 Gdansk59
All 81 locations
Target enrolment
to

Trials with a site in Gdansk

59 of 2705 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Recruiting
AstraZeneca
Phase 3
750
Gdansk, Gliwice, Kielce, Krakow, Lublin, Wroclaw
2026-09-24
Recruiting
AstraZeneca
Phase 3
1,330
Gdansk, Koszalin, Krakow, Lodz, Olsztyn, Poznan, Warsaw, Wroclaw
2026-09-15
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
230
Chęciny, Gdansk, Lodz
2026-07-24
Recruiting
AstraZeneca
Phase 3
915
Gdansk, Koszalin, Poznan, Siedlce, Skórzewo, Wroclaw
2026-07-16
Recruiting
AstraZeneca
Phase 3
750
Gdansk, Gliwice, Kielce, Lublin, Poznan, Wroclaw
2026-06-26
Recruiting
Ravulizumab Outcomes in Polish Patients With aHUS
NCT07399730Atypical Hemolytic Uremic Syndrome
DrugRavulizumab
AstraZeneca
Observational
80
Gdansk, Katowice, Krakow, Lodz, Poznan, Warsaw, Wroclaw
2026-06-24
Recruiting
AstraZeneca
Phase 3
150
Gdansk, Konin, Krakow, Lodz, Lublin, Poznan, Przemyśl, Wroclaw
2026-06-15
Recruiting
AstraZeneca
Phase 3
670
Gdansk, Krakow, Warsaw
2026-05-04
Recruiting
AstraZeneca
Phase 3
508
Gdansk, Gliwice, Lublin, Poznan, Warsaw, Wroclaw
2026-02-23
Recruiting
AstraZeneca
Phase 3
2,130
Gdansk, Koszalin, Krakow, Lublin, Olsztyn, Warsaw
2026-02-03
Recruiting
AstraZeneca
Phase 3
15,100
Bialystok, Bydgoszcz, Gdansk, Gdynia, Jelenia Góra, Katowice, Kędzierzyn-Koźle, Krakow
2025-06-04
Active, closed
AstraZeneca
Phase 3
3,103
Bialystok, Gdansk, Gdynia, Katowice, Kędzierzyn-Koźle, Krakow, Lodz, Lublin
2025-05-28
Recruiting
AstraZeneca
Observational
50
Bydgoszcz, Gdansk, Katowice, Krakow, L DZ, Lublin, Poznan, Szczecin
2025-05-15
Recruiting
AstraZeneca
Phase 3
1,220
Bydgoszcz, Gdansk, Koszalin, Lublin, Olsztyn, Warsaw
2025-05-06
Recruiting
AstraZeneca
Phase 3
600
Bialystok, Gdansk, Lodz, Poznan, Siedlce, Szczecin
2025-03-27
Recruiting
AstraZeneca
Phase 3
11,300
Bialystok, Biała Podlaska, Bydgoszcz, Chojnice, Chrzanów, Częstochowa, Gdansk, Gdynia
2025-03-14
Recruiting
AstraZeneca
Phase 3
840
Bialystok, Gdansk, Koszalin, Lodz, Olsztyn, Przemyśl, Tomaszów Mazowiecki, Warsaw
2025-03-01
Active, closed
AstraZeneca
Observational
105
Bydgoszcz, Bytom, Gdansk, Katowice, Krakow, Lodz, Lublin, Poznan
2025-02-28
Active, closed
Real-life Treatment Outcomes of Ravulizumab in PNH
NCT06633536Paroxysmal Nocturnal Haemoglobinuria
DrugRavulizumab
AstraZeneca
Observational
64
Bialystok, Brzozów, Bydgoszcz, Gdansk, Krakow, Lodz, Lublin, Opole
2025-02-06
Recruiting
AstraZeneca
Phase 3
1,018
Gdansk, Gliwice, Katowice, Krakow, Lublin, Warsaw, Wroclaw
2024-08-07
Recruiting
AstraZeneca
Phase 3
3,850
Biała Podlaska, Bielsko-Biala, Bydgoszcz, Chrzanów, Gdansk, Gdynia, Katowice, Kazimierza Wielka
2024-04-12
Active, closed
AstraZeneca
Phase 3
594
Bielsko-Biala, Gdansk, Katowice, Krakow, Lublin, Słupsk, Warsaw
2024-03-04
Recruiting
AstraZeneca
Phase 3
625
Bialystok, Bydgoszcz, Gdansk, Gdynia, Konin, Krakow, Legnica, Lodz
2023-11-23
Active, closed
AstraZeneca
Phase 3
5,511
Bialystok, Biała Podlaska, Bydgoszcz, Gdansk, Gdynia, Koszalin, Krakow, Lodz
2023-10-05
Recruiting
AstraZeneca
Phase 3
800
Bialystok, Gdansk, Gliwice, Krakow, Lodz, Poznan, Warsaw, Wroclaw
2023-09-22
Active, closed
AstraZeneca
Phase 3
594
Gdansk, Krakow, Poznan, Skórzewo
2022-09-15
Active, closed
AstraZeneca
Phase 3
607
Bydgoszcz, Gdansk, Katowice, Krakow, Lódz, Lublin
2022-09-12
Active, closed
AstraZeneca
Phase 2
194
Brzozów, Gdansk, Krakow, Lodz, Poznan, Warsaw
2022-08-11
Active, closed
AstraZeneca
Phase 3
1,051
Bydgoszcz, Gdansk, Koszalin, Poznan, Siedlce, Tomaszów Mazowiecki, Warsaw
2022-02-07
Active, closed
AstraZeneca
Phase 3
148
Gdansk, Gdynia, Krakow, Otwock, Poznan
2021-10-28
Active, closed
AstraZeneca
Phase 3
454
Gdansk, Olsztyn, Przemyśl, Warsaw
2021-10-28
Recruiting
AstraZeneca
Phase 1/2
460
Gdansk, Warsaw
2021-10-18
Active, closed
AstraZeneca
Phase 3
732
Bialystok, Gdansk, Gdynia, Konin, Koszalin, Lodz, Tomaszów Mazowiecki, Warsaw
2021-10-18
Active, closed
AstraZeneca
Phase 3
712
Gdansk, Nowa Sól, Skórzewo, Warsaw
2021-08-05
Active, closed
AstraZeneca
Phase 1
24
Bydgoszcz, Gdansk, Warsaw
2021-07-21
Active, closed
AstraZeneca
Phase 3
506
Gdansk, Krakow, Opole, Warsaw
2021-06-22
Recruiting
AstraZeneca
Phase 1
304
Gdansk, Krakow, Olsztyn, Tomaszów Mazowiecki, Warsaw
2021-03-09
Active, closed
AstraZeneca
Phase 1
155
Gdansk, Lodz, Lublin, Warsaw
2021-02-02
Active, closed
AstraZeneca
Phase 3
957
Bialystok, Gdansk, Krakow, Lodz, Poznan, Warsaw
2020-11-17
Active, closed
AstraZeneca
Phase 1/2
702
Bydgoszcz, Gdansk, Gdynia, Grzepnica, Lodz, Torun, Warsaw
2020-11-12
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
477
Bydgoszcz, Gdansk, Krakow, Poznan, Warsaw
2020-08-18
Active, closed
AstraZeneca
Phase 3
134
Chęciny, Gdansk, Lodz
2020-07-20
Active, closed
AstraZeneca
Phase 3
1,012
Bydgoszcz, Gdansk, Koszalin, Lodz, Olsztyn, Poznan, Rzeszów, Torun
2020-07-13
Active, closed
AstraZeneca
Phase 2
452
Gdansk, Konin, Koszalin, Krakow, Warsaw
2020-06-03
Active, closed
AstraZeneca
Phase 3
805
Gdansk, Lodz, Lublin, Olsztyn
2020-05-05
Active, closed
AstraZeneca
Phase 3
810
Gdansk, Lodz, Olsztyn, Poznan, Warsaw, Wroclaw
2019-04-16
Active, closed
AstraZeneca
Phase 3
724
Bydgoszcz, Elblag, Gdansk, Katowice, Lodz, Warsaw
2019-03-06
Active, closed
AstraZeneca
Phase 1
175
Bialystok, Bydgoszcz, Gdansk, Grudziądz, Lodz, Olsztyn, Tomaszów Mazowiecki, Warsaw
2018-12-27
Active, closed
AstraZeneca
Phase 1/2
243
Gdansk, Krakow, Lublin, Opole, Rzeszów, Warsaw
2018-12-21
Active, closed
AstraZeneca
Phase 3
407
Bialystok, Gdansk, Poznan, Tomaszów Mazowiecki, Warsaw
2018-11-27
Active, closed
AstraZeneca
Phase 3
1,063
Bialystok, Gdansk, Grudziądz, Koszalin, Krakow, Olsztyn, Ostrołęka, Poznan
2018-11-16
Active, closed
AstraZeneca
Phase 3
730
Gdansk, Olsztyn, Poznan, Tomaszów Mazowiecki, Warsaw, Wroclaw
2018-09-27
Active, closed
AstraZeneca
Phase 3
1,246
Bialystok, Gdansk, Grudziądz, Koszalin, Krakow, Olsztyn, Poznan, Radom
2018-09-27
Active, closed
AstraZeneca
Phase 3
1,018
Bialystok, Gdansk, Grudziądz, Koszalin, Piotrkow Trybunalski, Poznan, Warsaw, Wroclaw
2018-05-14
Active, closed
AstraZeneca
Phase 2
273
Dąbrowa Górnicza, Gdansk, Gdynia, Grzepnica, Krakow, Lodz, Olsztyn, Poznan
2018-03-07
Active, closed
AstraZeneca
Phase 3
1,126
Gdansk, Gdynia, Gliwice, Olsztyn, Otwock, Szczecin, Warsaw
2015-11-02
Active, closed
AstraZeneca
Phase 1
344
Gdansk, Krakow, Olsztyn, Poznan, Warsaw
2014-08-05
Active, closed
AstraZeneca
Phase 3
1,837
Gdansk, Grzepnica, Lodz, Olsztyn, Poznan, Warsaw
2014-04-22
Active, closed
AstraZeneca
Phase 3
510
Brzozów, Bydgoszcz, Gdansk, Grudziądz, Krakow, Lubin, Olsztyn, Opole
2013-09-25
Rows per page Showing 1–59 of 59
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 October 2026. https://priyalifescience.com/clinical-trials-poland/city/gdansk

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,705 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 59 of those studies with a site in Gdansk that also match the filters currently applied.

How many clinical trials are recruiting in Gdansk?

22 of the 59 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 37 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Gdansk), 59 studies
PhaseStudiesRecruitingShare
Phase 3431872.9%
Phase 1518.5%
Observational426.8%
Phase 2406.8%
Phase 1/2315.1%

Most active sponsors

Lead sponsors with the most studies (Gdansk)
Lead sponsorStudiesRecruiting
AstraZeneca5922
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.